Comparison of blood loss during Caesarean sections using Misoprostol placed within uterus as against placement inside rectum

Reduction in blood loss in Caesarean delivery following use of intra-uterine and rectal Misoprostol -A Comparative Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/062091

Enrollment

100

Registered

2024-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Misoprostol: 400 mcg of misoprostol administered intra-uterine(200 mcg in each cornua ) after delivery of placenta in Caesarean Deliveries Control Intervention1: Misoprostol: T .Misopro

Eligibility

Inclusion criteria

Inclusion criteria: Antenatal women more than 37 weeks of gestation planned for Elective LSCS

Exclusion criteria

Exclusion criteria: Fetal Anomalies Maternal Medical disorders Placenta previa ,Placenta accreta spectrum Known allergy to prostaglandin Previous 2 LSCS or more Patients requiring blood transfusion

Design outcomes

Primary

Measure	Time frame
Estimated blood lossTimepoint: Haemoglobin value 24 hours postoperatively	—

Secondary

Measure	Time frame
? Need for additional utero-tonic agents ? Need for blood transfusion ? Occurrence of PPH postoperatively within 24 hrs. ? Side-effects - pyrexia , shivering, loose motion etc Timepoint: monitored till discharge from hospital	—

Countries

India

Contacts

Public ContactDr PallaveeP

Mahatma Gandhi Medical College and Research Institute

drppallavee@gmail.com9489693270

Outcome results